Efficacy of Topical Cyclosporine Versus Tears for Improving Visual Outcomes Following Multifocal IOL Implantation

The purpose of this study is to evaluate the efficacy on quality of vision and dry eye signs and symptoms in patients undergoing cataract surgery using the ReZoom® multifocal IOL.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cataract Dry Eye Dry Eye Syndromes Eye Diseases Lacrimal Apparatus Diseases Lens Diseases

Age range

50 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Ophthalmic Consultants of Long Island

Rockville Centre, New York, 11570, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

· Males or females > 50 years old

Scheduled to undergo bilateral phacoemulsification with implantation of a multifocal IOL.
Likely to complete all study visits and able to provide informed consent
Visual potential of 20/25 or better

Exclusion criteria

· Prior use of topical cyclosporine

Known contraindications to any study medication or ingredients
Active ocular diseases or uncontrolled systemic disease
Active ocular allergies

Treatment and study plan

Topical Cyclosporine, Tears

Drug

Sponsors and collaborators

Lead sponsor

Innovative Medical

Industry

Registry information

Important dates

First posted: Jul 7, 2006
Registry last updated: Jun 1, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed